BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu A, Khawaja AP, Pasquale LR, Stein JD. A review of systemic medications that may modulate the risk of glaucoma. Eye (Lond) 2020;34:12-28. [PMID: 31595027 DOI: 10.1038/s41433-019-0603-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Ramulu PY. Neuroprotective Therapies for Patients With Worsening Glaucoma Despite Adequate Intraocular Pressure Lowering-Short-term Neurorecovery, Long-term Neuroprotection? JAMA Ophthalmol 2021. [PMID: 34792548 DOI: 10.1001/jamaophthalmol.2021.4573] [Reference Citation Analysis]
2 Marshall H, Mullany S, Qassim A, Siggs O, Hassall M, Ridge B, Nguyen T, Awadalla M, Andrew NH, Healey PR, Agar A, Galanopoulos A, Hewitt AW, MacGregor S, Graham SL, Mills R, Shulz A, Landers J, Casson RJ, Craig JE. Cardiovascular Disease Predicts Structural and Functional Progression in Early Glaucoma. Ophthalmology 2021;128:58-69. [PMID: 32730956 DOI: 10.1016/j.ophtha.2020.06.067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Sterling J, Hua P, Dunaief JL, Cui QN, VanderBeek BL. Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma. Br J Ophthalmol 2021:bjophthalmol-2021-319232. [PMID: 34413054 DOI: 10.1136/bjophthalmol-2021-319232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Thiermeier N, Lämmer R, Mardin C, Hohberger B. Erlanger Glaucoma Registry: Effect of a Long-Term Therapy with Statins and Acetyl Salicylic Acid on Glaucoma Conversion and Progression. Biology (Basel) 2021;10:538. [PMID: 34208432 DOI: 10.3390/biology10060538] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Hopper RG, Montiani-Ferreira F, da Silva Pereira J, Fritz MC, Ruggiero VJ, Sapienza JS, Kato K, Komáromy AM. Presumed neuroprotective therapies prescribed by veterinary ophthalmologists for canine degenerative retinal and optic nerve diseases. Vet Ophthalmol 2021;24:229-39. [PMID: 33682296 DOI: 10.1111/vop.12878] [Reference Citation Analysis]
6 Sharma S, Bhatia V. Nanoscale Drug Delivery Systems for Glaucoma: Experimental and In Silico Advances. Curr Top Med Chem 2021;21:115-25. [PMID: 32962618 DOI: 10.2174/1568026620666200922114210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Grzybowski A, Och M, Kanclerz P, Leffler C, Moraes CG. Primary Open Angle Glaucoma and Vascular Risk Factors: A Review of Population Based Studies from 1990 to 2019. J Clin Med 2020;9:E761. [PMID: 32168880 DOI: 10.3390/jcm9030761] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
8 Douglass A, Dattilo M, Feola AJ. Evidence for Menopause as a Sex-Specific Risk Factor for Glaucoma. Cell Mol Neurobiol 2022. [PMID: 34981287 DOI: 10.1007/s10571-021-01179-z] [Reference Citation Analysis]
9 Cvenkel B, Kolko M. Current Medical Therapy and Future Trends in the Management of Glaucoma Treatment. J Ophthalmol 2020;2020:6138132. [PMID: 32774906 DOI: 10.1155/2020/6138132] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]